Scholars Central

Conference abstract

Development of a novel autonomously replicating DNA vector platform for gene and cell therapy

Authors: Richard Harbottle Matthias Bozza Alicia Roig Merino James Williams Clague Hodgson Michael Milsom Dirk Jager, Patrick Schmidt

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The research of the DNA Vector Lab has most recently focused on the development of a next-generation non-viral DNA vector for gene and cell therapy and the genetic modification of cells. We have successfully built a novel DNA vector platform, which is uniquely suited for this purpose; it provides persistent expression and episomal maintenance without the use of potentially toxic viral components or the risk of insertional mutagenesis. We have demonstrated for the first time that non-integrating non-viral DNA vectors can be used comparably in applications to integrating vector systems such as Lentiviral and Sleeping Beauty vectors and with genome editing systems such as CRISPR; in some instances, our DNA vectors can be used where viruses cannot. We are applying our DNA vectors for gene therapy, for the generation of isogenic cell lines for tumour modelling and the genetic modification and therapeutic correction of clinically relevant human cells. We have recently made a breakthrough in our DNA vector design which allows the application of our vector in stem cells and primary human cells. For the first time, a non-integrating vector system can provide persistent transgene expression in primary human T-cells without the risk of integration-mediated genotoxicity, and we are currently developing a range of novel DNA vectors for anti-tumour immunotherapy. These DNA vectors can also be used to genetically modify stem cells, and we have recently shown that we can generate stable mouse embryonic cell lines and can generate transgenic mice from these modified cells. This presentation will illustrate the features of these novel DNA vectors and how we intend to leverage this new DNA Vector platform in projects which encompass T-Cell immunotherapy, stem cell therapy and prophylactic gene therapy for cancer.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiochemistry & Molecular Biology Journal
  • SubjectBiochemistry & Biotechnology
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Patrick Schmidt”